
## Abstract

### FUSED HETEROCYCLIC COMPOUND

The present invention provides a fused heterocyclic compound having a tyrosine kinase inhibitory action, which is represented by the formula:




(I)

wherein

$R^1$ is a hydrogen atom, a halogen atom, or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom;

$R^2$ is a hydrogen atom, or an optionally substituted group bonded via a carbon atom or a sulfur atom, or

$R^1$ and $R^2$, or $R^2$ and $R^3$ are optionally bonded to each other to form an optionally substituted ring structure;

$R^3$ is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or

$R^3$ is optionally bonded to the carbon atom on ring A to form an optionally substituted ring structure;

ring A is an optionally substituted benzene ring; and

ring B is

(i) an optionally substituted fused ring, or

(ii) a pyridine ring having optionally substituted carbamoyl (the pyridine ring is optionally further substituted).